PolyPid (NASDAQ:PYPD) is a clinical-stage specialty pharmaceutical company that develops and commercializes proprietary polymer–lipid hybrid (PLH) drug-delivery solutions designed to extend the duration of therapeutic agents and enhance patient compliance. Leveraging its patented Flexispheres™ technology, PolyPid creates controlled-release formulations that enable targeted, long-acting delivery of small molecules, peptides, and biologics. The company’s platform addresses a wide range of indications, from postoperative pain management to prevention of surgical site infections, by embedding active pharmaceutical ingredients within biodegradable polymer–lipid matrices for sustained local release.
The company’s leading product candidates include D-PLEX_UG™ and D-PLEX_YP™, depot formulations intended to prevent surgical site infections in general and pediatric surgeries, respectively. In preclinical and clinical studies, these candidates have demonstrated extended antimicrobial coverage with a single intraoperative administration, potentially reducing the need for systemic antibiotic prophylaxis. PolyPid is also advancing an injectable long-acting local anesthetic formulation aimed at providing up to seven days of postoperative pain relief from a single administration, positioning it as a potential alternative to continuous infusion catheters or repeated bolus injections.
Founded in 2004 and headquartered in Ness Ziona, Israel, with a U.S. subsidiary in Cambridge, Massachusetts, PolyPid combines its academic roots with industry-focused development practices. The company’s research and development efforts are supported by collaborations with leading academic institutions and contract-development organizations across North America and Europe. By maintaining a dual presence, PolyPid facilitates regulatory interactions with both the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA), while streamlining future manufacturing and commercialization pathways in key markets.
PolyPid is led by an experienced management team with deep expertise in pharmaceutical R&D, clinical development, and manufacturing. Its board of directors includes veteran biopharmaceutical and life sciences executives who have guided multiple programs through regulatory approval and market launch. The company’s strategic partnerships and advisory relationships further strengthen its capabilities in advancing long-acting drug therapies, underscoring its commitment to transforming the standard of care in surgery, pain management, and other high-need therapeutic areas.
